Showing results (191-200 of 231) with videos related to

Sort By:
Pageof 24
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Emotion (Washington, D.C.)|June 25, 2026
Childhood threat exposure and poor emotional awareness predict neural correlates of emotion regulation in adolescent girlsAdrienne S Bonar, Amy E Carolus, Adam Bryant Miller, et al.
Social Cognitive and Affective Neuroscience|October 26, 2022
Social goals in girls transitioning to adolescence: associations with psychopathology and brain network connectivityAndrea Pelletier-Baldelli, Margaret A Sheridan, Sarah Glier, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.
Pageof 24